JP Morgan Chase
CTIC

JP Morgan Chase’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

JP Morgan Chase’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,124,714
Closed -$4.72M – 7587
2023
Q1 		$4.72M Sell
1,124,714
-61,316
-5% -$318K ﹤0.01% 2866
2022
Q4 		$7.13M Buy
1,186,030
+46,920
+4% +$256K ﹤0.01% 2545
2022
Q3 		$6.63M Sell
1,139,110
-32,664
-3% -$204K ﹤0.01% 2486
2022
Q2 		$7M Buy
1,171,774
+1,167,902
+30,163% +$5.98M ﹤0.01% 2477
2022
Q1 		$18K Sell
3,872
-4,431
-53% -$13.2K ﹤0.01% 6097
2021
Q4 		$21K Buy
8,303
+1,020
+14% +$2.5K ﹤0.01% 6208
2021
Q3 		$21K Sell
7,283
-2,256
-24% -$6.14K ﹤0.01% 6042
2021
Q2 		$24K Buy
9,539
+1,938
+25% +$4.65K ﹤0.01% 5899
2021
Q1 		$22K Sell
7,601
-899
-11% -$2.94K ﹤0.01% 5692
2020
Q4 		$27K Sell
8,500
-38
-0.4% -$126 ﹤0.01% 5262
2020
Q3 		$9K Sell
8,538
-1
-0% -$1 ﹤0.01% 5279
2020
Q2 		$10K Buy
8,539
+39
+0.5% +$41 ﹤0.01% 5133
2020
Q1 		$8K Sell
8,500
-153,161
-95% -$176K ﹤0.01% 5087
2019
Q4 		$255K Sell
161,661
-129,820
-45% -$123K ﹤0.01% 4581
2019
Q3 		$243K Sell
291,481
-82,386
-22% -$62.9K ﹤0.01% 4538
2019
Q2 		$318K Sell
373,867
-30,610
-8% -$28.3K ﹤0.01% 4447
2019
Q1 		$392K Sell
404,477
-17,015
-4% -$17.9K ﹤0.01% 4324
2018
Q4 		$310K Sell
421,492
-147,240
-26% -$242K ﹤0.01% 4375
2018
Q3 		$1.23M Buy
568,732
+230,386
+68% +$570K ﹤0.01% 3789
2018
Q2 		$1.69M Buy
338,346
+70,594
+26% +$309K ﹤0.01% 3532
2018
Q1 		$1.04M Buy
267,752
+159,439
+147% +$561K ﹤0.01% 3647
2017
Q4 		$290K Buy
108,313
+22,865
+27% +$67K ﹤0.01% 4283
2017
Q3 		$272K Buy
+85,448
New +$285K ﹤0.01% 4014
2017
Q2 		– Sell
-7,662
Closed -$32K – 5504
2017
Q1 		$32K Buy
7,662
+6,962
+995% +$32.1K ﹤0.01% 4634
2016
Q4 		$3K Buy
700
+70
+11% +$290 ﹤0.01% 4926
2016
Q3 		$2K Sell
630
-682
-52% -$2.48K ﹤0.01% 4461
2016
Q2 		$4K Sell
1,312
-4,399
-77% -$20.2K ﹤0.01% 4518
2016
Q1 		$30K Sell
5,711
-4,164
-42% -$33.3K ﹤0.01% 4014
2015
Q4 		$121K Buy
+9,875
New +$132K ﹤0.01% 3753
2014
Q4 		– Sell
-1,791
Closed -$44K – 4562
2014
Q3 		$44K Buy
1,791
+606
+51% +$15.8K ﹤0.01% 4117
2014
Q2 		$34K Buy
1,185
+164
+16% +$4.93K ﹤0.01% 3469
2014
Q1 		$35K Hold
1,021
– – ﹤0.01% 3529
2013
Q4 		$20K Sell
1,021
-552
-35% -$10K ﹤0.01% 4015
2013
Q3 		$25K Sell
1,573
-8,484
-84% -$98.3K ﹤0.01% 4305
2013
Q2 		$106K Buy
+10,057
New +$118K ﹤0.01% 4145

Other funds holding CTIC

UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase's CTIC Position: Q2 2023 in Review

JP Morgan Chase sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 1,124,714 shares — an estimated $4.72M sold.

JP Morgan Chase first reported a position in CTIC in Q2 2013 and held it in 35 quarters. The position peaked at $7.13M in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

  • JP Morgan Chase reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
  • JP Morgan Chase sold 1,124,714 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $4.72M.
  • JP Morgan Chase first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 35 quarters.
  • JP Morgan Chase's CTI BioPharma Corp. (DE) Common Stock position peaked at $7.13M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on JP Morgan Chase's 13F filing for Q2 2023, filed 11 Aug 2023.